Niche Nanomedicine Target potential buyers and partners in the nanomedicine and precision healthcare space, highlighting Manhattan Scientific's focus on novel tech with disruption potential and the potential for sustainable business models.

Strong Leadership Tie‑ins Leverage connections to senior medical imaging and GE Healthcare expertise through the advisory board appointment of Michael J. Harsh to open conversations about advanced imaging solutions and strategic collaborations.

Strategic Growth Opportunities Position as an early-stage, high-innovation player seeking to scale; identify interest from small to mid-sized life sciences firms looking for disruptive tech platforms and favorable funding alignment.

Funding Readiness Note modest revenue and existing funding; tailor proposals that emphasize milestone-based funding, risk sharing, and potential ROI to investors or grant programs aligned with nanomedicine and imaging tech.

Tech & Partnerships Fit Emphasize compatibility with common tech stacks and digital platforms for collaboration; propose partnerships around research, data analytics, and go‑to‑market pilots leveraging existing tech tools.